Search
Prof Jonathan Carapetis has been elected as a new Fellow of the prestigious Australian Academy of Science in recognition of his pioneering, paradigm-shifting expertise in infectious diseases.
The Kids Research Institute Australia and Menzies School of Health Research have joined forces with Danila Dilba Health Service to look at improving treatment for RHD.
The END RHD CRE focuses priority research projects that will help achieve the singular target of producing the Endgame Strategy.
Learn more about the background and motivations of END RHD CRE Research Fellow Simone Reynolds.
After being diagnosed with rheumatic heart disease at ten, Elizabeth had to leave country and her family for a large chunk of her childhood so she could be treated in Adelaide.
When Liana complained of a sore foot and showed signs of a fever, her mum Margie rushed her to hospital. An X-ray of her foot revealed no obvious injury, so she was sent home and advised to take painkillers.
On 11 May 2017, over 60 attendees from throughout Australia convened in Darwin for a one-day Annual Meeting to discuss the progress of the END RHD CRE research projects, national RHD advocacy and the development of the final Endgame output.
The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non–coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results.
Acute rheumatic fever (ARF) is a multiorgan inflammatory disorder that results from the body's autoimmune response to pharyngitis or a skin infection caused by Streptococcus pyogenes (Strep A). Acute rheumatic fever mainly affects those in low- and middle-income nations, as well as in indigenous populations in wealthy nations, where initial Strep A infections may go undetected.
Group A Streptococcus (Strep A) is responsible for a significant global health and economic burden. The recent prioritization of Strep A vaccine development by the World Health Organization has prompted global research activities and collaborations. To progress this prioritization, establishment of robust surveillance for Strep A to generate updated regional disease burden estimates and to establish platforms for future impact evaluation is essential.